Answers are grounded in this paper and cite their sources.
Schizophrenia (SZ) is a severe mental disorder affecting emotion, cognitive and social functioning. Mitochondria, which are dysfunctional in the disease, are essential for neuronal function, synaptic plasticity and behavior, all impaired in SZ. A major driver of mitochondrial dysfunction in SZ is Complex I, particularly its NDUFV2 core subunit. We showed that NDUFV2 pseudogene (NDUFV2P1; PG) is upregulated in brain and peripheral cells of SZ patients and inversely correlates with NDUFV2 expression in brain specimens and with mitochondrial respiration in Epstein–Barr-virus-transformed lymphocyte cell lines (LCLs). Recently, we reported that PG competes with NDUFV2 mRNA for binding to RNA-binding proteins. We hypothesized that PG is a biologically functional pseudogene that regulates NDUFV2 expression, thereby affecting mitochondrial function and neuronal activity. Accordingly, we modulated PG abundance in LCLs and rat primary cortical neurons. PG overexpression in healthy-derived LCLs impaired mitochondrial membrane potential (Δψm), network dynamics, and oxygen consumption, while PG downregulation in SZ-derived LCLs normalized these parameters. In rat cortical neurons, PG overexpression induced comparable mitochondrial disruptions alongside impaired synapse formation and reduced spontaneous neuronal firing. This study provides evidence for a cellular pathway through which PG interference with NDUFV2 leads to SZ-related mitochondrial and neuronal deficits and suggests therapeutic potential for PG downregulation in diseases with bioenergetic impairments such as SZ.
No takes yet. Share an insight, caveat, or question.
Lapiro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: